Real-world research of advanced NSCLC immunotherapy based on iRECIST criteria

Real-world research of advanced NSCLC immunotherapy based on iRECIST criteria

Objective To analyze the real-world data about immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) based on the modified RECIST 1.1 for immune based therapeutics (iRECIST). Methods According to real-world research methods, all advanced NSCLC patients treated with immu...

Full description

Bibliographic Details
Main Authors: CHEN Mingjing, YANG Qiao, XU Zihan, LI Feng, YANG Guangrong, YOU Qi, YU Yongxin, SUN Jianguo
Format: Article
Language:zho
Published: Editorial Office of Journal of Third Military Medical University 2020-03-01
Series:Di-san junyi daxue xuebao
Subjects:
non-small cell lung cancer
immune checkpoint inhibitors
best overall response
progression-free survival
immune-related adverse events
Online Access:http://aammt.tmmu.edu.cn/Upload/rhtml/201910122.htm

Internet

http://aammt.tmmu.edu.cn/Upload/rhtml/201910122.htm

Similar Items